TY - JOUR
T1 - Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes
T2 - The EPIC Cohort
AU - Ose, Jennifer
AU - Schock, Helena
AU - Tjonneland, Anne
AU - Hansen, Louise
AU - Overvad, Kim
AU - Dossus, Laure
AU - Clavel-Chapelon, Francoise
AU - Baglietto, Laura
AU - Boeing, Heiner
AU - Trichopolou, Antonia
AU - Benetou, Vassiliki
AU - Lagiou, Pagona
AU - Masala, Giovanna
AU - Tagliabue, Giovanna
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Mattiello, Amalia
AU - Bueno-de-Mesquita, H. B(As)
AU - Peeters, Petra H. M.
AU - Onland-Moret, N. Charlotte
AU - Weiderpass, Elisabete
AU - Gram, Inger T.
AU - Sanchez, Soledad
AU - Obon-Santacana, Mireia
AU - Sanchez-Perez, Maria-Jose
AU - Larranaga, Nerea
AU - Huerta Castano, Jose Mara
AU - Ardanaz, Eva
AU - Brandstedt, Jenny
AU - Lundin, Eva
AU - Idahl, Annika
AU - Travis, Ruth C.
AU - Khaw, Kay-Tee
AU - Rinaldi, Sabina
AU - Romieu, Isabelle
AU - Merritt, Melissa A.
AU - Gunter, Marc J.
AU - Riboli, Elio
AU - Kaaks, Rudolf
AU - Fortner, Renee T.
PY - 2015/6
Y1 - 2015/6
N2 - Background: Evidence suggests an etiologic role for inflammation in ovarian carcinogenesis and heterogeneity between tumor subtypes and anthropometric indices. Prospective studies on circulating inflammatory markers and epithelial invasive ovarian cancer (EOC) have predominantly investigated overall risk; data characterizing risk by tumor characteristics (histology, grade, stage, dualistic model of ovarian carcinogenesis) and anthropometric indices are sparse.Methods: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate C-reactive protein (CRP), IL6, and EOC risk by tumor characteristics. A total of 754 eligible EOC cases were identified; two controls (n = 1,497) were matched per case. We used multivariable conditional logistic regression to assess associations.Results: CRP and IL6 were not associated with overall EOC risk. However, consistent with prior research, CRP >10 versus CRP 88: ORlog2, 1.78 (1.28-2.48), P-heterogeneityConclusions: Our data suggest that high CRP is associated with increased risk of overall EOC, and that IL6 and CRP may be associated with EOC risk among women with higher adiposity.Impact: Our data add to global evidence that ovarian carcinogenesis may be promoted by an inflammatory milieu. (C)2015 AACR.
AB - Background: Evidence suggests an etiologic role for inflammation in ovarian carcinogenesis and heterogeneity between tumor subtypes and anthropometric indices. Prospective studies on circulating inflammatory markers and epithelial invasive ovarian cancer (EOC) have predominantly investigated overall risk; data characterizing risk by tumor characteristics (histology, grade, stage, dualistic model of ovarian carcinogenesis) and anthropometric indices are sparse.Methods: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate C-reactive protein (CRP), IL6, and EOC risk by tumor characteristics. A total of 754 eligible EOC cases were identified; two controls (n = 1,497) were matched per case. We used multivariable conditional logistic regression to assess associations.Results: CRP and IL6 were not associated with overall EOC risk. However, consistent with prior research, CRP >10 versus CRP 88: ORlog2, 1.78 (1.28-2.48), P-heterogeneityConclusions: Our data suggest that high CRP is associated with increased risk of overall EOC, and that IL6 and CRP may be associated with EOC risk among women with higher adiposity.Impact: Our data add to global evidence that ovarian carcinogenesis may be promoted by an inflammatory milieu. (C)2015 AACR.
KW - C-REACTIVE PROTEIN
KW - BREAST-CANCER
KW - ANTHROPOMETRIC MEASURES
KW - MOLECULAR PATHOGENESIS
KW - PHYSICAL-ACTIVITY
KW - CENTRAL ADIPOSITY
KW - BODY-SIZE
KW - WOMEN
KW - OBESITY
KW - SERUM
U2 - 10.1158/1055-9965.EPI-14-1279-T
DO - 10.1158/1055-9965.EPI-14-1279-T
M3 - Article
C2 - 25855626
SN - 1055-9965
VL - 24
SP - 951
EP - 961
JO - Cancer Epidemiology Biomarkers & Prevention
JF - Cancer Epidemiology Biomarkers & Prevention
IS - 6
ER -